1-3 of 3
Lihua E. Budde
Close
Sort by
Journal Articles

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, Stephen J. Schuster, Chan Y. Cheah, Matthew Matasar, Gareth P. Gregory, Dok Hyun Yoon, Mazyar Shadman, Keith Fay, Sung-Soo Yoon, Carlos Panizo, Ian Flinn, Anna Johnston, Francesc Bosch, Laurie H. Sehn, Michael C. Wei, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4926–4935.
https://doi.org/10.1182/bloodadvances.2022009260
Published: 2023
Includes: Supplemental data
Journal Articles

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma

Clinical Trials & Observations
Craig A. Portell, Nolan A. Wages, Brad S. Kahl, Lihua E. Budde, Robert W. Chen, Jonathon B. Cohen, Nikole E. Varhegyi, Gina R. Petroni, Michael E. Williams
Journal: Blood Advances
Blood Adv (2022) 6 (5): 1490–1498.
https://doi.org/10.1182/bloodadvances.2021005357
Published: 2022
Includes: Supplemental data
Journal Articles

ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma

Clinical Trials & Observations
Steven I. Park, Thomas C. Shea, Oludamilola Olajide, Nishitha M. Reddy, Lihua E. Budde, Nilanjan Ghosh, Allison M. Deal, Jeanne F. Noe, Stephen M. Ansell
Journal: Blood Advances
Blood Adv (2020) 4 (11): 2548–2555.
https://doi.org/10.1182/bloodadvances.2020001871
Published: 2020
Includes: Supplemental data